Vicore Pharma Announces Presentations at the European Respiratory Society (ERS) International Congress 2023

Vicore Pharma Announces Presentations at the European Respiratory Society (ERS) International Congress 2023

Stockholm, September 6, 2023 – Vicore Pharma Holding AB (publ), unlocking the potential of a new class of drug candidates, angiotensin II type 2 receptor agonists (ATRAGs), announced today that it will present two posters on its lead program, C21, under development for the treatment of idiopathic pulmonary fibrosis (IPF), at the European Respiratory Society (ERS) International Congress 2023 in Milan, Italy September 9-13.

Title: Characterization of high responders in the phase 2a IPF AIR trial of C21 using baseline quantitative CT image analysis

Presenting Author: Rohit Batta, Chief Medical Officer

Date and Time: Monday, September 11, 2023, 16:00 – 17:30 CET

Location: Session 349, PS-18

Title: An open label, pharmacodynamic trial investigating vascular effects of the angiotensin II type 2 receptor agonist (ATRAG) C21

Presenting Author: Elin Rosendahl, Vice President Clinical Development

Date and Time: Monday, September 11, 2023, 16:00 – 17:30 CET

Location: Session 350, PS-19

“We are delighted to present data on C21, our lead molecule for the treatment of IPF, at this year's ERS conference,” said Ahmed Mousa, incoming CEO of Vicore Pharma. “The data being presented reflect the transformative potential of ATRAGs for patients suffering with IPF from a mechanistic perspective and the exciting lung function data generated in the Phase 2a AIR study to date. These presentations come as Vicore prepares to initiate its Phase 2b ASPIRE study for C21 in the first half of next year.”

The posters to be presented at ERS are now available on the Vicore Pharma website.

About C21

C21 is a first-in-class oral small molecule ATRAG under development for the treatment of idiopathic pulmonary fibrosis (IPF). C21 has received an orphan drug designation for IPF both in Europe and the United States. The novel mechanism of action of C21 targets fibrosis by stimulating the protective arm of the renin-angiotensin system.  Angiotensin II type 2 receptor activation triggers protective signaling pathways, promoting alveolar repair and maintenance of alveolar integrity.

For further information, please contact:

Hans Jeppsson, CFO

Phone: +46 70 553 14 65

E-mail: hans.jeppsson@vicorepharma.com

This information was submitted for publication on September 6 at 08:00 CEST.

About Vicore Pharma Holding AB (publ)

Vicore is an innovative Swedish clinical-stage pharmaceutical company unlocking the potential of a new class of drugs to stop disease progression and restore function. The company is establishing a portfolio in rare lung diseases including idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH). C21 is a first-in-class orally available small molecule angiotensin II type 2 receptor agonist (ATRAG) currently in a phase 2a study of IPF. C21 is protected by US and European orphan drug designation. A variety of patents have been filed to provide further protection for C21, out to 2040 and onwards. Almee™ (an investigational medical device in clinical development) is a digital therapeutic (DTx) based on cognitive behavioral therapy (CBT) created to address the psychological impact of living with pulmonary fibrosis. Inhaled IMID is a new formulation and delivery route of thalidomide targeting the severe cough associated with IPF. Using its unique expertise in the ATRAG biology Vicore is further fueling its pipeline with several new small molecule drug assets, with long patent life and for a variety of indications, some of which could be partnered while others may be taken to the market by Vicore. The company’s shares (VICO) are listed on Nasdaq Stockholm’s main market. For more information, see www.vicorepharma.com.